JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Cellebrite DI (NASDAQ:CLBT) Stock

Cellebrite DI (NASDAQ:CLBT) had its price objective upped by analysts at JPMorgan Chase & Co. from $24.00 to $28.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 9.98% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC raised their price target on Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, January 22nd. Craig Hallum lifted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI presently has an average rating of “Buy” and a consensus target price of $22.14.

Cellebrite DI Trading Up 0.2 %

CLBT stock opened at $25.46 on Tuesday. Cellebrite DI has a 12-month low of $8.91 and a 12-month high of $26.30. The company has a market cap of $5.24 billion, a price-to-earnings ratio of -16.43, a PEG ratio of 3.72 and a beta of 1.47. The firm has a 50 day moving average of $22.31 and a 200-day moving average of $18.89.

Institutional Trading of Cellebrite DI

A number of hedge funds have recently bought and sold shares of CLBT. Juncture Wealth Strategies LLC lifted its stake in shares of Cellebrite DI by 0.8% during the 4th quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company’s stock worth $1,322,000 after purchasing an additional 505 shares during the period. Strategic Advisors LLC boosted its stake in Cellebrite DI by 3.4% in the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company’s stock worth $641,000 after buying an additional 950 shares during the last quarter. Steward Partners Investment Advisory LLC grew its holdings in Cellebrite DI by 12.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock valued at $299,000 after buying an additional 1,463 shares during the period. Tower View Wealth Management LLC increased its stake in shares of Cellebrite DI by 1.2% during the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company’s stock valued at $2,200,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Quarry LP purchased a new position in shares of Cellebrite DI during the 3rd quarter worth about $27,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.